Cameron Turtle - 15 Jan 2025 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: SYRE
Reported as of: 15 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jan 2025, 16:35:13 UTC
Prior SEC filing: 06 Sep 2024
Next SEC filing: 03 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones, as Attorney-in-Fact

Key filing fact

Cameron Turtle filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 17 Jan 2025.

Key facts

This page summarizes Cameron Turtle's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jan 2025, 16:35.

Change

Previous filing in this sequence was filed on 06 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYRE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +370,000
Change %
Price: $0.000000
Shares after: 370,000
Date: 15 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 370,000
Exercise price: $21.66
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase 370,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC remarks

Exhibit 24 - Power of Attorney